[Back]
Univ.-Prof. Mag. Dr. Thierry Langer
Thierry Langer
T: +43-1-4277-55103
https://cheminfo.univie.ac.at/people/principal-investigator/thierry-langer/
Summer term 2024
251393 VO Pharmazeutische Chemie (synthetische und semisynthetische Arzneistoffe) (VO)
301817 UE MPM 6 - Practical Course: Pharmacoinformatics and structure-based drug design
321029 VO Pharmazeutische Chemie 2 - B15
322005 VO (Bio)pharmazeutika mit Wirkung auf das Herz-Kreislauf System - M4
322006 VO (Bio)pharmazeutika mit Wirkung auf das Nervensystem - M5
322022 VU Ausgewählte Kapitel aus der pharmazeutisch-chemischen Forschung - M13
323001 VU Introduction to Drug Discovery and Preclinical Drug Development - MPS1
323002 UE Introduction to Experimental Methods in Drug Discovery and Preclinical Drug Development - MPS1
323008 SE Case Studies in Drug Discovery and Preclinical Drug Development - MPS7 - (2 Courses)
323101 VU Pharmacoinformatics - MPS5
Winter term 2023
262005 VO Introduction to Computational Biology and Drug Discovery
321001 VO Steop Einführung in die pharmazeutischen Wissenschaften - B1
321028 VO Pharmazeutische Chemie 1 - B15
322001 VO (Bio)pharma. mit Wirkung auf metabol. Störungen & eingeschr. Organ- und Systemfunktionen - M1
322002 VO Antiinfektiva, Antineoplastika und (Bio)pharmazeutika mit Wirkung auf das Immunsystem - M2
322022 VU Ausgewählte Kapitel aus der pharmazeutisch-chemischen Forschung - M13
323001 VU Introduction to Drug Discovery and Preclinical Drug Development - MPS1
323003 VO Basics of Drug Discovery - MPS2
323004 VO Drug Discovery - MPS3
Summer term 2023
251393 VO Pharmazeutische Chemie (synthetische und semisynthetische Arzneistoffe) (VO)
301817 UE MPM 6 - Practical Course: Pharmacoinformatics and structure-based drug design
321029 VO Pharmazeutische Chemie 2 - B15
322005 VO (Bio)pharmazeutika mit Wirkung auf das Herz-Kreislauf System - M4
322006 VO (Bio)pharmazeutika mit Wirkung auf das Nervensystem - M5
322022 VU Ausgewählte Kapitel aus der pharmazeutisch-chemischen Forschung - M13
323001 VU Introduction to Drug Discovery and Preclinical Drug Development - MPS1
323002 UE Introduction to Experimental Methods in Drug Discovery and Preclinical Drug Development - MPS1
323008 SE Case Studies in Drug Discovery and Preclinical Drug Development - MPS7 - (2 Courses)
323101 VU Pharmacoinformatics - MPS5
201 - 216 out of 216
Bendix F, Adaktylos P, Wolber G, Langer T. CINF 111-2D and 3D Visualization of pharmacophoric ligand-receptor interaction. American Chemical Society. Abstracts of Papers (at the National Meeting). 2006 Sep 10;232.
Schuster D, Langer T. Parallel pharmacophoric profiling as lead optimization tool for the prediction of interactions via the cytochrome P450 enzyme family. American Chemical Society. Abstracts of Papers (at the National Meeting). 2006 Sep 10;232:75-75.
Langer T, Hoffmann RD. Pharmacophore modelling: applications in drug discovery. Expert Opinion on Drug Discovery. 2006 Aug;1(3):261-267. doi: 10.1517/17460441.1.3.261
Kirchmair J, Wolber G, Laggner C, Langer T. Comparative performance assessment of the conformational model generators omega and catalyst: A large-scale survey on the retrieval of protein-bound ligand conformations. Journal of Chemical Information and Modeling. 2006 Jul 24;46(4):1848-1861. doi: 10.1021/ci060084g
Ortuso F, Langer T, Alcaro S. GBPM: GRID-based pharmacophore model: concept and application studies to protein-protein recognition. Bioinformatics. 2006 Jun 15;22(12):1449-1455. doi: 10.1093/bioinformatics/btl115
Schuster D, Maurer EM, Laggner C, Nashev LG, Wilckens T, Langer T et al. The discovery of new 11 beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening. Journal of Medicinal Chemistry. 2006 Jun 15;49(12):3454-3466. doi: 10.1021/jm0600794
Cucarull-Gonzalez JR, Laggner C, Langer T. Influence of the conditions in pharmacophore generation, scoring, and 3D database search for chemical feature-based pharmacophore models: One application study of ET(A)- and ET(B)-selective antagonists. Journal of Chemical Information and Modeling. 2006 May;46(3):1439-1455. doi: 10.1021/ci060006t
Schuster D, Laggner C, Steindl TM, Palusczak A, Hartmann RW, Langer T. Pharmacophore modeling and in silico screening for new P450 19 (aromatase) inhibitors. Journal of Chemical Information and Modeling. 2006 May;46(3):1301-1311. doi: 10.1021/ci050237k
Langer T. Feature-based pharmacophores as a tool for activity profiling: Application examples. American Chemical Society. Abstracts of Papers (at the National Meeting). 2006 Mar 26;231.
Rollinger JM, Mock P, Zidorn C, Ellmerer EP, Langer T, Stuppner H. Erratum: Application of the in combo screening approach for the discovery of non-alkaloid acetylcholinesterase inhibitors from Cichorium intybus (Current Drug Discovery Technologies (2005) 2, (185-193)). Current Drug Discovery Technologies. 2006 Mar;3(1):89. doi: 10.2174/157016306776637582
Schuster D, Steindl TM, Langer T. Predicting Drug Metabolism Induction In Silico. Current Topics in Medicinal Chemistry. 2006;6(15):1627-1640. doi: 10.2174/156802606778108924
Rollinger JM, Mock P, Zidorn C, Ellmerer EP, Langer T, Stuppner H. Application of the in combo screening approach for the discovery of non-alkaloid acetylcholinesterase inhibitors from Cichorium intybus. Current Drug Discovery Technologies. 2005 Sep;2(3):185-193. doi: 10.2174/1570163054866855
Rollinger JM, Bodensieck A, Seger C, Ellmerer EP, Bauer R, Langer T et al. Discovering COX-inhibiting constituents of Morus root bark: Activity-guided versus computer-aided methods. Planta Medica. 2005 May;71(5):399-405. doi: 10.1055/s-2005-864132
Kirchmair J, Laggner C, Wolber G, Langer T. Comparative Analysis of Protein-Bound Ligand Conformations with Respect to Catalyst's Conformational Space Subsampling Algorithms. Journal of Chemical Information and Modeling. 2005 Jan 12;45(2):422-430. doi: 10.1021/ci0497531
Rollinger JM, Hornick A, Langer T, Stuppner H, Prast H. Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products. Journal of Medicinal Chemistry. 2004 Dec 2;47(25):6248-6254. doi: 10.1021/jm049655r
Rollinger JM, Haupt S, Stuppner H, Langer T. Combining ethnopharmacology and virtual screening for lead structure discovery: COX-inhibitors as application example. Journal of Chemical Information and Computer Sciences. 2004;44(2):480-488. doi: 10.1021/ci030031o
201 - 216 out of 216

Towards Next Generation Pharmacophore Modeling: Concepts and Applications

Thierry Langer (Speaker)

21 Dec 2022

Activity: Talks and presentations › Talk or oral contribution › Science to Public

Pharmacophore Models: Useful Tools for Bio-Active Compound Identification, Optimization, and Profiling

Thierry Langer (Speaker)

15 Dec 2022

Activity: Talks and presentations › Talk or oral contribution › Science to Public

Pharmacophores: Versatile Tools for Computer-Assisted Molecular Design

Thierry Langer (Speaker)

18 Jul 2022

Activity: Talks and presentations › Talk or oral contribution › Science to Public

Approaches to Next Generations Pharmacophore Modeling

Thierry Langer (Speaker)

29 Jun 2022

Activity: Talks and presentations › Talk or oral contribution › Science to Public

Pharmacophores: Versatile Tools for Computer-Assisted Molecular Design

Thierry Langer (Speaker)

25 May 2022

Activity: Talks and presentations › Talk or oral contribution › Science to Public

In silico and in vitro Approach to Assess Direct Allosteric AMPK Activators from Nature

Benjamin Kirchweger (Speaker), Andreas Wasilewicz (Contributor), Katrin Fischhuber (Contributor), Ammar Tahir (Contributor), Ya Chen (Contributor), Elke Heiß (Contributor), Thierry Langer (Contributor), Johannes Kirchmair (Contributor) & Judith Maria Rollinger (Contributor)

20 May 2022

Activity: Talks and presentations › Talk or oral contribution › Science to Science

Academic Drug Discovery: Pittfalls and Bottlenecks

Thierry Langer (Speaker)

11 May 2022

Activity: Talks and presentations › Talk or oral contribution › Science to Public

A Computational Approach to Identify Potential Novel Inhibitors Against The Coronavirus SARS-CoV-2

Ernst Urban (Speaker), Thierry Langer (Speaker), Thomas Seidel (Speaker), Oliver Wieder (Speaker) & Arthur Garon (Speaker)

28 Jul 2020

Activity: Talks and presentations › Talk or oral contribution › Science to Science

New Approaches to Analyze Big Data: The Molecular Dynamics Trajectory Case

Thierry Langer (Speaker)

28 Nov 2019

Activity: Talks and presentations › Talk or oral contribution › Other

Towards Next Generation Pharmacophores: Concepts and Applications

Thierry Langer (Speaker)

24 Nov 2019

Activity: Talks and presentations › Talk or oral contribution › Other

Adventures in Computer-Assisted Molecular Design

Thierry Langer (Speaker)

16 Sep 2019

Activity: Talks and presentations › Talk or oral contribution › Other

Towards Next Generation Pharmacophores: Concepts and Applications

Thierry Langer (Speaker)

21 May 2019

Activity: Talks and presentations › Talk or oral contribution › Other

Towards next Generation Pharmacophores: Concepts and Application

Thierry Langer (Speaker)

20 Mar 2019

Activity: Talks and presentations › Talk or oral contribution › Science to Public

Towards Next Generation Pharmacophores: Concepts and Applications

Thierry Langer (Speaker)

20 Mar 2019

Activity: Talks and presentations › Talk or oral contribution › Other

Pharmacophore Modelling: How to Enhance Virtual Screening Efficacy in Early Drug Discovery

Thierry Langer (Speaker)

23 Jan 2019

Activity: Talks and presentations › Talk or oral contribution › Other

Discovery of new GPBAR1 agonists by combined in silico - in vitro screening

Benjamin Kirchweger (Speaker), Jadel Müller Kratz (Contributor), Angela Ladurner (Contributor), Ulrike Grienke (Contributor), Verena Dirsch (Contributor), Thierry Langer (Contributor) & Judith Maria Rollinger (Contributor)

26 Aug 2018

Activity: Talks and presentations › Talk or oral contribution › Science to Science

Pharmacophore-based Analysis of MD Trajectories: Towards Understanding KD of Protein Ligands

Thierry Langer (Speaker)

5 Jul 2018

Activity: Talks and presentations › Talk or oral contribution › Other

Pharmacophore-based Analysis of MD Trajectories: Towards Understanding KD of Protein Ligands

Thierry Langer (Speaker)

2 Jul 2018

Activity: Talks and presentations › Talk or oral contribution › Other

Adventures in Computer-Assisted Molecular Design

Thierry Langer (Speaker)

29 Jun 2018

Activity: Talks and presentations › Talk or oral contribution › Other

Generation of Structure-based Pharmacophore Models in Protein Binding Sites Obtained from Molecular Dynamics Simulations

Thierry Langer (Speaker)

29 May 2018

Activity: Talks and presentations › Talk or oral contribution › Other

Pharmacophore-based Analysis of MD Trajectories: Towards Understanding KD of Protein Ligands

Thierry Langer (Speaker)

22 May 2018

Activity: Talks and presentations › Talk or oral contribution › Other

In silico tools for early phase side effect profiling and off target prediction of potential drug candidates

Thierry Langer (Speaker)

5 Apr 2018

Activity: Talks and presentations › Talk or oral contribution › Other

MD Derived Feature-based Pharmacophores: A New Way to Enhance Virtual Screening Efficacy in Multitarget Drug Discovery

Thierry Langer (Speaker)

16 Mar 2018

Activity: Talks and presentations › Talk or oral contribution › Other

Dynamic Pharmacophores: A New Way to Enhance Virtual Screening Efficacy in Early Drug Discovery

Thierry Langer (Speaker)

28 Jan 2018

Activity: Talks and presentations › Talk or oral contribution › Other

Dynamic Pharmacophores: A New Way to Enhance Virtual Screening Efficacy in Early Drug Discovery

Thierry Langer (Speaker)

16 Nov 2017

Activity: Talks and presentations › Talk or oral contribution › Other

In Silico Tools for Early Drug Discovery

Thierry Langer (Speaker)

14 Nov 2017

Activity: Talks and presentations › Talk or oral contribution › Other

Metabolism & Bioisosteres in Medicinal Chemistry

Thierry Langer (Speaker)

19 Oct 2017

Activity: Talks and presentations › Talk or oral contribution › Other

Activity Profiling & Toxicity Prediction Using Inte:Ligand's LigandScout KNIME Extensions

Thierry Langer (Speaker)

9 Oct 2017

Activity: Talks and presentations › Talk or oral contribution › Other

Adventures in Computer-Aided Molecular Design

Thierry Langer (Speaker)

12 Sep 2017

Activity: Talks and presentations › Talk or oral contribution › Other

Towards next Generation Pharmacophore Models: Concepts and Applications

Thierry Langer (Speaker)

25 Aug 2017

Activity: Talks and presentations › Talk or oral contribution › Other

3D Pharmacophores for Hit and Lead Identification: Current and Future Aspects

Thierry Langer (Speaker)

26 May 2017

Activity: Talks and presentations › Talk or oral contribution › Other

Dynamic Pharmacophore and the Common Hits Approach: A Novel Method for Enhancing Virtual Screening Efficiency

Thierry Langer (Speaker)

23 May 2017

Activity: Talks and presentations › Talk or oral contribution › Other

Dynamic pharmacophores and the common hits approach: a novel method for enhancing virtual screening efficiency

Thierry Langer (Speaker)

23 May 2017

Activity: Talks and presentations › Talk or oral contribution › Other

3D Pharmacophores for Hit and Lead Identification: Current and Future Aspects

Thierry Langer (Speaker)

26 Apr 2017

Activity: Talks and presentations › Talk or oral contribution › Other

Pharmacophore Approaches for Polypharmacoliogical Profiling of Compound Libaries

Thierry Langer (Speaker)

8 Feb 2017

Activity: Talks and presentations › Talk or oral contribution › Other

Introduction to Ligand-Based Drug Design: Pharmacophore Methods

Thierry Langer (Speaker)

18 Jan 2017

Activity: Talks and presentations › Talk or oral contribution › Other

Seminarvortrag

Thierry Langer (Speaker)

12 Dec 2016

Activity: Talks and presentations › Talk or oral contribution › Other

Department of Pharmaceutical Sciences

Head

Josef-Holaubek-Platz 2 (UZA II)
1090 Wien
Room: 2D306

T: +43-1-4277-55103

thierry.langer@univie.ac.at